ArticleCancer diagnosis & prognosis

Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Akifumi Kuwano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.